LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 26

Search options

  1. Article ; Online: Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?

    Elias, Roy / Antonarakis, Emmanuel S

    Translational cancer research

    2023  Volume 12, Issue 10, Page(s) 2448–2453

    Language English
    Publishing date 2023-10-03
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2901601-0
    ISSN 2219-6803 ; 2218-676X
    ISSN (online) 2219-6803
    ISSN 2218-676X
    DOI 10.21037/tcr-23-1279
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Kidney Cancer Updates from the 2023 American Society of Clinical Oncology Annual Meeting in Chicago.

    Elias, Roy / Ged, Yasser / Singla, Nirmish

    Kidney cancer journal : official journal of the Kidney Cancer Association

    2024  Volume 21, Issue 2, Page(s) 58–63

    Abstract: This report highlights key research from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) across clinical trials and translational studies. ... ...

    Abstract This report highlights key research from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) across clinical trials and translational studies. Essential updates in the metastatic ccRCC clinical space encompass results from the CONTACT-03 study, which evaluated an immunotherapy containing regimen for patients who progressed on an initial immunotherapy containing regimen, alongside updated results from the KEYNOTE-426 and CLEAR trials. In the metastatic nccRCC domain, we review clinical trials of combination immunotherapies and tyrosine kinase inhibitors (TKIs). Additionally, we highlight exciting early-phase studies exploring novel targets in RCC and engineered T-cell methodologies. Finally, we summarize notable efforts in translational research, emphasizing biomarker investigations to determine predictors of immunotherapy response, the application of molecular classifiers in RCC, and the relationship between the microbiome and RCC. There were many important RCC related abstracts presented at this year's ASCO conference, attesting to the continued momentum of research in the field. All conference materials, including abstracts and presentations, can be accessed online through the conference website.
    Language English
    Publishing date 2024-01-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2244563-8
    ISSN 1933-0871 ; 1933-0863
    ISSN (online) 1933-0871
    ISSN 1933-0863
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine.

    Elias, Roy / Sharma, Akanksha / Singla, Nirmish / Brugarolas, James

    Kidney cancer journal : official journal of the Kidney Cancer Association

    2020  Volume 17, Issue 4, Page(s) 94–104

    Language English
    Publishing date 2020-04-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2244563-8
    ISSN 1933-0871 ; 1933-0863
    ISSN (online) 1933-0871
    ISSN 1933-0863
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities.

    Elias, Roy / Zhang, Qing / Brugarolas, James

    Cancer journal (Sudbury, Mass.)

    2020  Volume 26, Issue 5, Page(s) 390–398

    Abstract: The discovery of the von Hippel-Lindau (VHL) gene marked a milestone in our understanding of clear cell renal cell carcinoma (ccRCC) pathogenesis. VHL inactivation is not only a defining feature of ccRCC, but also the initiating event. Herein, we discuss ...

    Abstract The discovery of the von Hippel-Lindau (VHL) gene marked a milestone in our understanding of clear cell renal cell carcinoma (ccRCC) pathogenesis. VHL inactivation is not only a defining feature of ccRCC, but also the initiating event. Herein, we discuss canonical and noncanonical pVHL functions, as well as breakthroughs shaping our understanding of ccRCC evolution and evolutionary subtypes. We conclude by presenting evolving strategies to therapeutically exploit effector mechanisms downstream of pVHL.
    MeSH term(s) Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/therapy ; Genes, Tumor Suppressor ; Humans ; Kidney Neoplasms/genetics ; Kidney Neoplasms/therapy ; Von Hippel-Lindau Tumor Suppressor Protein/genetics
    Chemical Substances Von Hippel-Lindau Tumor Suppressor Protein (EC 2.3.2.27) ; VHL protein, human (EC 6.3.2.-)
    Language English
    Publishing date 2020-09-24
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
    ZDB-ID 2018400-1
    ISSN 1540-336X ; 1528-9117 ; 1081-4442
    ISSN (online) 1540-336X
    ISSN 1528-9117 ; 1081-4442
    DOI 10.1097/PPO.0000000000000480
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma.

    Sharma, Akanksha / Elias, Roy / Christie, Alana / Williams, Noelle S / Pedrosa, Ivan / Bjarnason, Georg A / Brugarolas, James

    Kidney cancer (Clifton, Va.)

    2023  Volume 7, Issue 1, Page(s) 15

    Abstract: This corrects the article DOI: 10.3233/KCA-210117.]. ...

    Abstract [This corrects the article DOI: 10.3233/KCA-210117.].
    Language English
    Publishing date 2023-03-23
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 2961890-3
    ISSN 2468-4570 ; 2468-4562
    ISSN (online) 2468-4570
    ISSN 2468-4562
    DOI 10.3233/KCA-229030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: High-Grade, Nonsarcomatoid Chromophobe Renal Cell Carcinoma: A Series of 22 Cases With Novel Molecular Features on a Subset.

    Baraban, Ezra G / Elias, Roy / Lin, Ming-Tseh / Ged, Yasser / Zhu, Jing / Pallavajjala, Aparna / Singla, Nirmish / Lotan, Tamara L / Argani, Pedram / Eshleman, James R / Epstein, Jonathan I

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

    2024  Volume 37, Issue 5, Page(s) 100472

    Abstract: Chromophobe renal cell carcinoma (ChRCC) is the third most common subtype of renal cell carcinoma and typically exhibits indolent behavior, though a rare subset can exhibit high-grade morphologic features and is associated with a poor prognosis. Although ...

    Abstract Chromophobe renal cell carcinoma (ChRCC) is the third most common subtype of renal cell carcinoma and typically exhibits indolent behavior, though a rare subset can exhibit high-grade morphologic features and is associated with a poor prognosis. Although there are limited data on the molecular characteristics of metastatic and sarcomatoid ChRCC, the molecular features of high-grade, nonsarcomatoid ChRCC remain unexplored. Herein, we characterize 22 cases of ChRCC with high-grade, nonsarcomatoid components. High-grade ChRCC frequently demonstrated advanced stage at diagnosis (64% ≥pT3a or N1), with regions of extrarenal extension, nodal metastases, and vascular invasion consisting solely of high-grade ChRCC morphologically. We performed spatially guided panel-based DNA sequencing on 11 cases comparing high-grade and low-grade regions (n = 22 samples). We identified recurring somatic alterations emblematic of ChRCC, including deletions of chromosomes 1, 2, 6, 10, 13, 17, and 21 in 91% (10/11) of cases and recurring mutations in TP53 (81.8%, n = 9/11) and PTEN (36.4%, n = 4/11). Notably, although PTEN and TP53 alterations were found in both high-grade and low-grade regions, private mutations were identified in 3 cases, indicating convergent evolution. Finally, we identified recurring RB1 mutations in 27% (n = 3) of high-grade regions leading to selective protein loss by immunohistochemistry not observed in adjacent low-grade regions. This finding was confirmed in The Cancer Genome Atlas cohort where 2 of 66 cases contained RB1 mutations and demonstrated unequivocal high-grade, nonsarcomatoid morphology. We also detected multiple chromosomal gains confined to the high-grade regions, consistent with imbalanced chromosome duplication. These findings broaden our understanding of the molecular pathogenesis of ChRCC and suggest that subclonal RB1 mutations can drive the evolution to high-grade, nonsarcomatoid ChRCC.
    Language English
    Publishing date 2024-03-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645073-8
    ISSN 1530-0285 ; 0893-3952
    ISSN (online) 1530-0285
    ISSN 0893-3952
    DOI 10.1016/j.modpat.2024.100472
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back.

    Elias, Roy / Kapur, Payal / Pedrosa, Ivan / Brugarolas, James

    Clinical genitourinary cancer

    2018  Volume 16, Issue 6, Page(s) 485–488

    MeSH term(s) Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Chemoradiotherapy/methods ; Clinical Deterioration ; Fatal Outcome ; Hospices ; Humans ; Lung Neoplasms/pathology ; Lung Neoplasms/secondary ; Lung Neoplasms/therapy ; Male ; Pleural Effusion, Malignant/diagnostic imaging ; Pleural Effusion, Malignant/pathology ; Pleural Effusion, Malignant/therapy ; Radiosurgery ; Treatment Outcome ; Tumor Burden/drug effects ; Tumor Burden/radiation effects
    Language English
    Publishing date 2018-07-20
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2225121-2
    ISSN 1938-0682 ; 1558-7673
    ISSN (online) 1938-0682
    ISSN 1558-7673
    DOI 10.1016/j.clgc.2018.07.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.

    Yin, Jianyi / Elias, Roy / Peng, Lan / Levonyak, Nicholas / Asokan, Annapoorani / Christie, Alana / Kubiliun, Nisa / Brugarolas, James / Hammers, Hans J

    Clinical genitourinary cancer

    2022  Volume 20, Issue 3, Page(s) 260–269

    Abstract: Introduction: Immune checkpoint inhibitors (ICIs) have become a standard of care in metastatic renal cell carcinoma (mRCC) but are associated with immune-related adverse events (irAEs) including colitis. Growing evidence suggests proton pump inhibitors ( ...

    Abstract Introduction: Immune checkpoint inhibitors (ICIs) have become a standard of care in metastatic renal cell carcinoma (mRCC) but are associated with immune-related adverse events (irAEs) including colitis. Growing evidence suggests proton pump inhibitors (PPIs) increase the risk of inflammatory bowel disease (IBD). Given the pathophysiological overlap between IBD and ICI colitis, we sought to evaluate the relationship between PPI use and ICI colitis in mRCC patients.
    Patients and methods: We performed a retrospective study of adult patients who received ICI therapy for mRCC between 2015 and 2018 at University of Texas Southwestern Medical Center affiliated hospitals. Clinical characteristics, oncological outcomes, ICI colitis details, and PPI use details were collected by manual chart review. The diagnosis of ICI colitis was made via biopsy when available, or by clinical criteria (symptoms and response to immunosuppressive therapy) when biopsy specimens were unavailable or inconclusive. Univariable and multivariable logistic regression analyses were conducted to assess the potential contribution of PPIs to ICI colitis.
    Results: A total of 176 patients received ICI therapy for mRCC, of which 16 (9.1%) were diagnosed with ICI colitis. Patients with ICI colitis presented with elevated stool lactoferritin and calprotectin and a wide range of endoscopic and histologic findings. There were no significant differences between patients with and without ICI colitis in age, gender, medical comorbidities, RCC history, and overall survival. However, exposure to ipilimumab and PPI use were more frequently observed in patients with ICI colitis than those without. In univariable and multivariable logistic regression analyses, exposure to ipilimumab and chronic use of PPIs > 8 weeks were significantly associated with ICI colitis.
    Conclusion: In addition to ipilimumab use, chronic use of PPIs may be associated with ICI colitis in patients with mRCC.
    MeSH term(s) Adult ; Carcinoma, Renal Cell/drug therapy ; Colitis/chemically induced ; Colitis/drug therapy ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Inflammatory Bowel Diseases/drug therapy ; Ipilimumab/therapeutic use ; Kidney Neoplasms/drug therapy ; Proton Pump Inhibitors/adverse effects ; Retrospective Studies
    Chemical Substances Immune Checkpoint Inhibitors ; Ipilimumab ; Proton Pump Inhibitors
    Language English
    Publishing date 2022-02-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2225121-2
    ISSN 1938-0682 ; 1558-7673
    ISSN (online) 1938-0682
    ISSN 1558-7673
    DOI 10.1016/j.clgc.2022.01.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.

    Sharma, Akanksha / Elias, Roy / Christie, Alana / Williams, Noelle S / Pedrosa, Ivan / Bjarnason, Georg A / Brugarolas, James

    Kidney cancer (Clifton, Va.)

    2022  Volume 6, Issue 1, Page(s) 69–79

    Abstract: Background: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose escalation for other ... ...

    Abstract Background: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose escalation for other TKIs has been shown to afford added disease control.
    Objective: We sought to evaluate whether dose escalation of cabozantinib (Cabometyx
    Methods: We identified patients with mRCC at the University of Texas Southwestern Medical Center who were treated with cabozantinib dose escalation to 80 mg after progressing on conventional cabozantinib 60 mg. We then queried leading kidney cancer investigators across the world to identify additional patients. Finally, we reviewed pharmacokinetic (PK) data to assess how higher doses impacted circulating levels by comparison to other formulations (Cometriq
    Results: We report six patients treated at two different institutions with cabozantinib-responsive disease and good tolerability, where cabozantinib was dose escalated (typically to 80 mg, but as high as 120 mg) after progression on 60 mg, a strategy that resulted in added disease control (median duration, 14 months; 95% Confidence Interval [CI]: 8 - Not Estimable[NE]). Four patients (66.7%) had disease control lasting at least 1 year. No grade III/IV adverse events were identified in this small, select, cohort. A comparison of PK data to FDA-approved cabozantinib 140 mg capsules suggest that cabozantinib 80 mg tablets results in comparable exposures.
    Conclusions: mRCC patients with cabozantinib responsive disease and reasonable tolerability may benefit from dose escalation at progression.
    Language English
    Publishing date 2022-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2961890-3
    ISSN 2468-4570 ; 2468-4562
    ISSN (online) 2468-4570
    ISSN 2468-4562
    DOI 10.3233/kca-210117
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Life-threatening hemoptysis in patients with metastatic kidney cancer.

    Patel, Viral M / Elias, Roy / Asokan, Annapoorani / Sharma, Akanksha / Christie, Alana / Pedrosa, Ivan / Chiu, Hsienchang / Reznik, Scott / Hannan, Raquibul / Timmerman, Robert / Brugarolas, James

    Clinical genitourinary cancer

    2023  Volume 21, Issue 4, Page(s) 497–506

    Abstract: Hemoptysis is a complication of intrathoracic tumors, both primary and metastatic, and the risk may be increased by procedural interventions as well as Stereotactic Ablative Radiation (SAbR). The risk of hemoptysis with SAbR for lung cancer is well ... ...

    Abstract Hemoptysis is a complication of intrathoracic tumors, both primary and metastatic, and the risk may be increased by procedural interventions as well as Stereotactic Ablative Radiation (SAbR). The risk of hemoptysis with SAbR for lung cancer is well characterized, but there is a paucity of data about intrathoracic metastases. Here, we sought to evaluate the incidence of life-threatening/fatal hemoptysis (LTH) in patients with renal cell carcinoma (RCC) chest metastases with a focus on SAbR. We systematically evaluated patients with RCC at UT Southwestern Medical Center (UTSW) Kidney Cancer Program (KCP) from July 2005 to March 2020. We queried Kidney Cancer Explorer (KCE), a data portal with clinical, pathological, and experimental genomic data. Patients were included in the study based on mention of "hemoptysis" in clinical documentation, if they had a previous bronchoscopy, or had undergone SAbR to any site within the chest. Two hundred and thirty four patients met query criteria and their records were individually reviewed. We identified 10 patients who developed LTH. Of these, 4 had LTH as an immediate procedural complication whilst the remaining 6 had prior SAbR to ultra-central (UC; abutting the central bronchial tree) metastases. These 6 patients had a total of 10 lung lesions irradiated (UC, 8; central 1, peripheral 1), with a median total cumulative SAbR dose of 38 Gray (Gy/ lesion) (range: 25-50 Gy). Other risk factors included intrathoracic disease progression (n = 4, 67%), concurrent anticoagulant therapy (n = 1, 17%) and concurrent systemic therapy (n = 4, 67%). Median time to LTH from first SAbR was 26 months (range: 8-61 months). Considering that 130 patients received SAbR to a chest lesion during the study period, the overall incidence of LTH following SAbR was 4.6% (6/130). The patient population that received SAbR (n = 130) was at particularly high risk for complications, with 67 (52%) having two or more chest metastaes treated, and 29 (22%) receiving SAbR to three or more lesions. Overall, the risk of LTH following SAbR to a central or UC lesion was 10.5% (6/57). In conclusion, SAbR of RCC metastases located near the central bronchial tree may increase the risk of LTH.
    MeSH term(s) Humans ; Carcinoma, Renal Cell/secondary ; Lung Neoplasms/surgery ; Kidney Neoplasms/pathology ; Radiosurgery/adverse effects
    Language English
    Publishing date 2023-02-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2225121-2
    ISSN 1938-0682 ; 1558-7673
    ISSN (online) 1938-0682
    ISSN 1558-7673
    DOI 10.1016/j.clgc.2023.01.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top